Loading...
Cardiff Oncology Q1 2025 Earnings Report
Cardiff Oncology reported its financial results for the first quarter of 2025, showing a net loss of $13.434 million and a decrease in cash and cash equivalents.
Key Takeaways
Cardiff Oncology, Inc. reported a net loss of $13.434 million for the first quarter of 2025, compared to a net loss of $10.011 million for the same period in 2024. Total revenues decreased to $0.109 million from $0.205 million year-over-year. The company's cash and cash equivalents stood at $24.095 million as of March 31, 2025, down from $51.470 million at the end of 2024. Operating expenses increased significantly, driven by higher research and development costs.
Net loss for Q1 2025 was $13.434 million, an increase from $10.011 million in Q1 2024.
Total revenues decreased to $0.109 million in Q1 2025 from $0.205 million in Q1 2024, primarily from royalties.
Cash and cash equivalents decreased to $24.095 million as of March 31, 2025, from $51.470 million at December 31, 2024.
Operating expenses rose to $14.491 million in Q1 2025 from $11.138 million in Q1 2024, mainly due to increased research and development costs.
Revenue by Segment
Forward Guidance
Cardiff Oncology expects to continue incurring losses and requiring additional capital to advance its clinical trial programs. The company believes its current cash resources are sufficient to fund operations into the first quarter of 2027.
Positive Outlook
- Sufficient cash to meet funding requirements for at least the next 12 months following the issuance date of the financial statements.
- Projected cash runway extends into the first quarter of 2027.
- Ongoing clinical trials for onvansertib in multiple indications, including RAS-mutated mCRC, mPDAC, SCLC, and TNBC.
- FDA agreement for a seamless Phase 3 trial with an interim ORR endpoint for accelerated approval.
- Positive preliminary efficacy data from TROV-054 Phase 1b/2 trial in KRAS-mutated mCRC, with an ORR of 29% across evaluable patients.
Challenges Ahead
- Expectation to continue incurring net losses for the foreseeable future.
- Anticipated need for additional capital to further advance clinical trial programs and support other operations.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...